Pharma's Market
SPECIAL REPORT
MOST SHARED
- Greece Pours $22.6 Billion Into Four Biggest Banks
- Europe Has Wall Street's Bull on a Short Leash
- Greece to Leave Euro Zone on June 18: Wealth Manager
- Spain's Borrowing Costs Near Danger Level: Bailout Next?
- Winemaking Lures the Wealthy, But Not With Profits
- Collectors Wary Of Investing In Josh Hamilton
- The Shortage of Women Billionaires
- 5 Spots Where the Dollar Buys a Great Vacation
- 10 Ways to Save Money by Spending More
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- Spain's Debt Costs Near Danger Level: Is Bailout Next?
- US Markets Will Be Watching Europe—And Jobs Report
- European Companies Plan for Greek Unrest and Euro Exit
- Public Pensions Faulted for Bets on Rosy Returns
- Greece to Leave Euro Zone on June 18: Wealth Manager
- Italy 2-Year Borrowing Costs at Peak Since December
- Euro Bond Wins Supporters, but Details Remain Vague
- German, UK Bond Yields Will Go Even Lower
- Labor Board Member Resigns Over Leak to GOP Allies
RSS FEED
Vivus' Race Against The Clock
Text Size 
CNBC Correspondent
Vivus is getting the JPMorgan Healthcare Conference off to a sexy start.
The company announced this morning that its late-stage experimental erectile dysfunction drug apparently gets the job done in 15 minutes.
Depending on the dosage, 67-72 percent of men in the study said they were ready to do it within a quarter hour. That's way faster than Pfizer's Viagra, Lilly's Cialis and Levitra from GlaxoSmithKline, Merck and Bayer.
Vivus officials call those results "surprising."
The company plans to file for FDA approval of the pill by the end of this year. It recently filed for the agency okay of its diet drug Qnexa. Arena Pharmaceuticals is also seeking regulatory approval of a weightloss pill. Orexigen is expected to submit its application soon for a third diet pill.
Finally, it looks like the coach of my USC Trojans will be going to work for billionaire biotech backer and Seattle Seahawks owner Paul Allen. I am not joining the chorus of boo-birds that thinks Pete Carroll has betrayed them. Sure, I hope his bolting doesn't mean the SC football program is on the verge of getting into trouble with the NCAA, but this is the nature of the beast and the business. So, thank you, Coach, for a decade of college football dominance, great times and fantastic memories. All the best in Seattle. Fight On!
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes
